yoshi ichikawa

* Led chemistry aspect of product development of DIFICID * Developing/establishing IP portfolio/market exclusive strategy, * Business development: completed partnering of DIFICID (presentation, deal negotiation) as a team member and alliance management for collaboration * Business development/due diligence for in/out-licensing * Let team to complete CMC package of OPT-822/OPT-821 (cancer antigen, Globo H-protein conjugate) as an immunotherapy for breast cancer

Course Director of Bioorganic Mechanisms course and Teaching enzyme reaction mechanisms, protein conjugation chemistry and Drug Development - Developed extremely potent sugar and nucleoside-based inhibitors as molecular probes to study reaction mechanisms of key metabolic enzymes in sugar metabolic pathway, oligosaccharide biosynthesis and nucleotide repair process

Consulting biotechs for inlicensing opportunities.

* Advised and worked directly with team members to accomplish corporate goals in multi-disciplinary areas: * Business Development: Searched and evaluated inlicensing opportunities in acute care and prepared a package of outlicensing pipeline opportunities * Legal Department (IP): Developed and established patent portfolio and market exclusivity * Discovery Research: Helped put scientists in contact with academic and biotech contacts in US and Japan. Helped establish a joint research project related microbiome. * International/Alliance Management: Managed alliance partner for DIFICID/DIFICLIR on CMC and IP

* Business development for partnering the core technology platform OPopS, and established several collaborations with pharmaceutical companies. * Led these collaborations as the program leader and they were: * gt; De novo glycosylation on peptides to improve PK/half-life * gt; A novel carbohydrate-based iron chelator for anemia * gt; Chemical synthesis of a series of heparin analogues * Established a commercial manufacturing method for cancer antigen oligosaccharide-protein conjugates * Business development for inlicensing: search/evaluation and completed a licensing negotiation of antibiotic from Japan * Business development for partnering of DIFICID for global markets * Developing IP portfolio of DIFICID and the macrolide antibiotics

* Led discovery team to develop a new class of macrolide antibacterial agents, which was effective against resistant pathogens (solithromycin) * Construct cancer antigen oligosaccharide-protein conjugates as active immunotherapy for breast cancer (OPT-822/OPT-821) * Established the core technology platform OPopS (carbohydrate for drug discovery)

It is becoming increasingly recognized that bacterial antibiotic resistance is outstripping the development of new antibiotic therapeutics, and some authorities even warn of a return to the pre-antibiotic era, where life-threatening infections cannot be successfully treated. The objective of Macrolide Pharmaceuticals is to develop new, fifth generation macrolide antibiotics active against a variety of organisms, especially gram-negative bacteria, and with both intravenous and oral availability.

* Developed and established IP portfolio and market exclusive strategy of DIFICID * Business development: Led a team of search and evaluation of in-licensing opportunities and prepared summary reports with recommendation to the senior executive team * Alliance management for IP, development and CMC activities

Developed and established the first large scale chemo-enzymatic synthetic methods for complex oligosaccharides with co-factors in situ regeneration","Extensive studies in enzyme specificity in oligosaccharide synthesis","Designing inhibitors of enzymes necessary for oligosaccharide biosynthesis and metabolism"]

1. Chemical synthesis of a series of insect hormone derivatives as potential safe pestisides as a undergraduate 2. Chemical synthetic study of brassinolide, which is the newest steroidal plant hormone during a master course 3. Chemical synthesis of heparin penta-saccharide with high affinity to antithrombin III from a disaccharide cellubiose as the building block as a doctor thesis (RIKEN/The University of Tokyo) Activities and Societies: Natural product systhesis, steroids, pheromone, complex oligosaccharides

Designed and prepared novel carbohydrate derivatives as molecular probes to study carbohydrate-protein interactions (lectins) to determine the required conformation of oligosaccharides and requirement of the functional groups of carbohydrate for the maximum binding to their lectins"]